ENGN NASDAQ
enGene Holdings Inc.
1W: +6.2%
1M: -82.1%
3M: -84.8%
YTD: -82.7%
1Y: -55.6%
$1.53
-0.04 (-2.55%)
Weekly Expected Move ±43.5%
$0
$1
$2
$2
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$78.3M
52W Range1.4-12.25
Volume1,420,033
Avg Volume1,446,301
Beta-0.01
Dividend—
Analyst Ratings
Company Info
CEORonald H. W. Cooper
Employees56
SectorHealthcare
IndustryBiotechnology
IPO Date2022-02-01
Websiteengene.com
7171 Rue Frederick Banting
Saint-Laurent H4S 1Z9
CA
Saint-Laurent H4S 1Z9
CA
514 332 4888
About enGene Holdings Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
Why Is enGene Therapeutics Stock Falling Friday?
enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Dow Dips 350 Points; US Foods Posts Downbeat Earnings
12 Health Care Stocks Moving In Thursday's Intraday Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| CHEUNG ANTHONY TZEYE | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Giguere Lee | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Nichols Alexander Ju | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Daws D. Ryan | A-Award | 220,000 | $9.53 | 2026-01-30 |
| Cooper Ronald Harold | A-Award | 801,000 | $9.53 | 2026-01-30 |